Intelligent Bio Solutions Inc (NASDAQ:INBS) shares traded 92.51% higher at $0.44 on Wall Street last session.
In accordance with the data, 1 analysts cover Intelligent Bio Solutions Inc (NASDAQ:INBS). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $10.00, we find $10.00. Given the previous closing price of $0.23, this indicates a potential upside of 4247.83 percent. INBS stock price is now -45.43% away from the 50-day moving average and -86.97% away from the 200-day moving average. The market capitalization of the company currently stands at $1.99M.
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $10.00 as their price target over the next twelve months.
In other news, Simeonidis Harry, CEO bought 50 shares of the company’s stock on Sep 01. The stock was bought for $92 at an average price of $1.85. Upon completion of the transaction, the CEO now directly owns 4,180 shares in the company, valued at $1839.2. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 31, CEO Simeonidis Harry bought 100 shares of the business’s stock. A total of $192 was incurred on buying the stock at an average price of $1.92. This leaves the insider owning 4,130 shares of the company worth $1817.2. A total of 58.93% of the company’s stock is owned by insiders.
Intelligent Bio Solutions Inc (NASDAQ: INBS) opened at $0.3651 on Thursday. During the past 12 months, Intelligent Bio Solutions Inc has had a low of $0.20 and a high of $32.00. As of last week, the company has a debt-to-equity ratio of 0.35, a current ratio of 0.65, and a quick ratio of 0.48. The fifty day moving average price for INBS is $0.8008 and a two-hundred day moving average price translates $3.3541 for the stock.
The latest earnings results from Intelligent Bio Solutions Inc (NASDAQ: INBS) was released for Jun, 2023. According to the Medical Devices Company, earnings per share came in at -$1.91, missing analysts’ expectations of -$1.49 by -0.42. This compares to -$1.63 EPS in the same period last year. The net profit margin was -845.89% and return on equity was -203.99% for INBS. For the current quarter, analysts expect INBS to generate $950k in revenue.
Intelligent Bio Solutions Inc(INBS) Company Profile
Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
